Check for updates

OPEN ACCESS

EDITED BY A. M. Abd El-Aty, Cairo University, Egypt

REVIEWED BY Mohammad Nejatian, Baqiyatallah University of Medical Sciences, Iran Khashayar Sarabandi, Research Institute of Food Science and Technology (RIFST), Iran Milad Ashrafizadeh, Sabanci University, Türkiye Raj Kumar, University of Nebraska Medical Center, United States

*CORRESPONDENCE Sara Sohrabvandi ⊠ sohrabv@sbmu.ac.ir Elham Khanniri ⊠ e.khanniri@sbmu.ac.ir Neda Mollakhalili-Meybodi ⊠ neda_mabodi@yahoo.com

RECEIVED 17 October 2023 ACCEPTED 20 March 2024 PUBLISHED 03 April 2024

CITATION

Shakeri M, Ghobadi R, Sohrabvandi S, Khanniri E and Mollakhalili-Meybodi N (2024) Co-encapsulation of omega-3 and vitamin D₃ in beeswax solid lipid nanoparticles to evaluate physicochemical and *in vitro* release properties. *Front. Nutr.* 11:1323067.

doi: 10.3389/fnut.2024.1323067

COPYRIGHT

© 2024 Shakeri, Ghobadi, Sohrabvandi, Khanniri and Mollakhalili-Meybodi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Co-encapsulation of omega-3 and vitamin D₃ in beeswax solid lipid nanoparticles to evaluate physicochemical and *in vitro* release properties

Mohammad Shakeri¹, Runak Ghobadi¹, Sara Sohrabvandi²*, Elham Khanniri²* and Neda Mollakhalili-Meybodi³*

¹Department of Food Science and Technology, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran, ²Department of Food Technology Research, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran, ³Department of Food Sciences and Technology, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

In recent years, lipophilic bioactive compounds have gained much attention due to their wide range of health-benefiting effects. However, their low solubility and susceptibility to harsh conditions such as high temperatures and oxidation stress have limited their potential application for the development of functional foods and nutraceutical products in the food industry. Nanoencapsulation can help to improve the stability of hydrophobic bioactive compounds and protect these sensitive compounds during food processing conditions, thus overcoming the limitation of their pure use in food products. The objective of this work was to co-entrap vitamin D_3 (VD₃) and omega 3 (ω 3) as hydrophobic bioactive compounds providing significant health benefits in beeswax solid lipid nanoparticles (BW. SLNs) for the first time and to investigate the effect of different concentrations of VD₃ (5 and 10 mg/mL) and ω_3 (8 and 10 mg) on encapsulation efficiency (EE). Our findings revealed that the highest EE was obtained for VD₃ and ω 3 at concentrations of 5 mg/mL and 10 mg, respectively. $VD_3/\omega3$ loaded BW. SLNs ($VD_3/\omega3$ -BW. SLNs) were prepared with zeta potential and size of-32 mV and 63.5 nm, respectively. Results obtained by in-vitro release study indicated that VD_3 release was lower compared to $\omega 3$ in the buffer solution. VD₃ and w3 incorporated in BW. SLNs demonstrated excellent stability under alkaline and acidic conditions. At highly oxidizing conditions, 96.2 and 90.4% of entrapped VD₃ and ω 3 remained stable in nanoparticles. Moreover, nanoparticles were stable during 1 month of storage, and no aggregation was observed. In conclusion, co-loaded VD_3 and $\omega 3$ in BW. SLNs have the great potential to be used as bioactive compounds in food fortification and production of functional foods.

KEYWORDS

beeswax, omega-3, simultaneous entrapment, solid lipid nanoparticles, vitamin D₃

1 Introduction

The incorporation of hydrophobic bioactive components such as essential oils, fat-soluble vitamins, drugs, nutraceuticals, antimicrobials, and flavors into supplements, pharmaceuticals, and functional foods pose many challenges owing to their low solubility in water and inadequate bio-accessibility that need to be mixed with aqueous media to be suitable for oral administration (1, 2). One of the most efficient strategies to overcome the solubility issue and bioavailability is using nano-delivery systems. Since lipid colloidal carriers like waxes or fats have biocompatibility with lipid matrices, they are recognized as suitable nano-delivery systems in the food industry to encapsulate lipophilic bioactive compounds (3). In addition, lipid-based nanocarriers have a high specific surface area, leading to improved bioavailability and biodistribution of loaded bioactives (4, 5).

Nanotechnology has brought out new methods for food processing that aim to enhance physicochemical properties and the stability and availability of nutrients (6). Nanoparticles have remarkable mesoscopic characteristics such as increased surface area, elevated reactivity, minuscule particle size, enhanced strength, quantum effects, and ductility, making them highly sought-after in several industries (7). Flavoring agents, preservatives, encapsulated food components, and other nanoparticles and nanoscale food additives are used to modify the nutritional content and improve the shelf life, scent, and texture of food products (8). At present, encapsulation is viewed as an efficient approach that could increase the intake of sensitive chemicals via products by delaying oxidation and hiding the disagreeable taste of specific components (9).

Lipid-based nanoparticles are known as solid lipid nanoparticles (SLNs), which were first known in 1991 by Müller and gained the attention of researchers worldwide for the delivery of molecules with low bioavailability and poor solubility. SLNs are composed of a solid core containing solid (rather than liquid) lipids with a high melting point dispersed in an aqueous surfactant solution. Lipids used in the manufacture of the nanoparticles are in the solid state at 25°C and the average size of nanoparticles is in the range of 40-1,000 nm (10, 11). SLNs have many advantages over traditional colloidal carriers such as polymeric nanoparticles, emulsions, and liposomes (11, 12). Hence, they have potential applications in the pharmaceutical field and food industry as carriers for antimicrobial compounds or lipophilic bioactives and dermatological and cosmetic preparations (13). Studies have shown that the physicochemical and structural properties of SLNs depend on their ingredients and processes of production. It means that the size of particles, long-term stability, release behavior, loading capacity, and encapsulation efficiency of hydrophobic bioactive components are affected by the SLN formulation in terms of selected surfactants and lipids and their composition (14, 15). Lipid substances used in the fabrication of SLNs should be generally recognized as safe (GRAS). Beeswax is one of the components that can be used as a solid lipid with a melting temperature of 61-67°C for the preparation of SLNs owing to its low toxicity, biodegradability, and low cost (16, 17). In fact, liquids secreted by special wax glands in the abdomen of worker bees are called beeswax, which changes to a solid state in contact with air (18). It consists of hydrocarbons, free fatty acids, saturated and unsaturated linear and complex monoesters, alcohols, and other minor compounds (19). Therefore, due to the hydrophobic properties of beeswax, it is a proper matrix for lipid-soluble compounds.

Co-encapsulation of more than one bioactive component is a suitable technique to increase their functionality and bioactivity compared to a single bioactive by inducing synergistic effects between ingredients. In recent years, co-delivery systems have been widely applied in the food and pharmaceutical industries to maintain the stability of certain active components or cure specific diseases (20, 21). For example, omega-3 fish oil has been shown to have strong oxidative stability when co-encapsulated with α -tocopherol (22). In a study conducted by Xiao et al. (23), it was stated that co-encapsulation of fish oil with garlic essential oil exhibited the highest oxidative stability during 30 days of storage. Similarly, Tchuenbou-Magaia et al. (24) reported that co-encapsulated rutin enhanced the activity and stability of vitamin D₃ and the chitosan-zein microparticles could be a suitable delivery system for the enrichment of food products with vitamin D₃.

Omega-3 fatty acids are essential bioactive compounds with physiological functions such as combating neural disorders, preventing cardiovascular diseases, and improving memory processing (25). One of the issues of producing fortified foods with omega-3 fatty acids is the autoxidation of long-chain polyunsaturated fatty acids, which causes rancidity and reduced shelf life (26). Cholecalciferol (vitamin D₃) is a liposoluble pro-hormone that is involved in the maintenance of calcium and phosphorus homeostasis (27, 28). People with metabolic (hyperparathyroidism and obesity) or gastrointestinal diseases, as well as those who do not receive enough sunshine exposure, often have vitamin D₃ deficiencies (29). Deficiency of vitamin D₃ can lead to rickets and osteoporosis. Also, it has an important role in the prevention of diseases such as cancer (30). Since vitamin D_3 and omega-3 fatty acids (ω 3) are hydrophobic compounds, they cannot be easily dispersed into formulations of aqueous food. Therefore, it is necessary to create efficient delivery mechanisms to overcome these obstacles and to enable the incorporation of these bioactive lipids into different functional foods. On the other hand, the co-entrapment of omega-3 and vitamin D₃ in SLNs has not been evaluated yet. Thus, the present work aimed at the co-encapsulation of fat-soluble vitamin D_3 (VD₃) and omega 3 (ω 3) in beeswax solid lipid nanoparticles (BW. SLNs) to increase the stability of both these bioactive compounds. The obtained results concerning size, zeta potential, morphology analysis of nanoparticles, encapsulation efficiency, the *in-vitro* release of VD₃ and ω_3 and their stability under different conditions are presented and discussed.

2 Materials and methods

2.1 Materials

Beeswax (BW) with a melting point of $60-66^{\circ}$ C and purity of 99%, vitamin D₃ (VD₃), omega 3 (Docosahexaenoic acid), and egg yolk lecithin were purchased from Sigma Chemical Co (St Louis, Mo., United States). Tween-80 was obtained from Merck (Germany). All the solvents used in this research were of the highest commercially accessible grade.

2.2 Preparation of VD₃/ ω 3-BW. SLNs, VD₃-BW. SLNs, ω 3-BW. SLNs and unloaded BW. SLNs

The production of VD_3/ω 3-BW. SLNs were accomplished using a Nano-emulsion method (31), as shown in Figure 1. Briefly, BW (25 mg), lecithin (7.3 mg), VD₃ (5 and 10 mg/mL ethanol), and $\omega 3$ (8 and 10 mg) were heated to a temperature of 90 $^\circ$ C in a water bath inside a glass tube with a screw cap. In a similar way, 5 mL of distilled water (aqueous phase) containing (0.8% v/v) tween 80 was heated at 90°C for 10 min and then added to the mixture of molten beeswax and lecithin, which resulted in the formation of an emulsion. The emulsion was gently stirred for 1 min, and an ultrasonic homogenizer was used to disperse it at a frequency of 24 kHz within 2 min. Finally, to facilitate the production of VD_3/ω 3-BW. SLNs, this emulsion was slowly poured into 50 mL of cold water at a temperature of 4°C with a volume ratio of 1:10 using a syringe and stirred with a magnetic stirrer at a speed of 1,100 rpm. Also, this approach was applied to prepare VD₃-BW. SLNs, and ω3-BW. SLNs with an optimal concentration of VD₃ and ω3, respectively, and unloaded BW. SLNs (U-BW. SLNs). Table 1 displays the various concentrations of VD₃ and ω 3 used in the production process of VD₃/ ω 3-BW. SLNs to determine the best formula, which was used for size and zeta analysis, morphology, and stability tests.

2.3 Characterization of unloaded and loaded BW. SLNs

2.3.1 Determining the yield of BW. SLNs

The yield of prepared BW. SLNs was measured by freeze-drying 10 mL of the prepared BW. SLNs. Afterward, the produced nanoparticles were weighed, and the total mass of the sample was determined.

2.3.2 Morphology analysis

The morphology of nanoparticles was evaluated using a scanning electron microscope (SEM) (JEOL LSM5600LV). The centrifugation process was used to purify samples of both unloaded and loaded BW. SLNs. The produced nanoparticles were frozen at -20° C and then dried in a freeze drier. These samples were utilized for analysis by SEM.



TABLE 1 The different concentrations of vitamin D₃ and omega 3 utilized in the production of VD₃/03-BW. SLNs to determine the optimal formulation.

Formulation*	Vitamin D3 (mg/ml)	Omega 3 (mg)	Size (nm)	Vitamin D₃ EE (%)	Omega 3 EE (%)
VD ₃ /ω3-BW. SLNs	5	8	72.30 ± 2.40^{a}	$89.70\pm1.50^{\rm a}$	$81.70\pm1.90^{\rm b}$
VD ₃ /ω3-BW. SLNs	5	10	$63.50\pm4.00^{\rm b}$	$92.30\pm1.20^{\rm a}$	$86.30\pm1.40^{\rm a}$
VD ₃ /ω3-BW. SLNs	10	8	67.80 ± 1.80^{ab}	$91.80\pm1.80^{\rm a}$	82.30 ± 1.50^{ab}
VD ₃ /ω3-BW. SLNs	10	10	65.10 ± 2.50^{ab}	92.70 ± 2.00^{a}	85.40 ± 1.80^{ab}

*VD3-BW. SLNs: vitamin D3/omega 3-beeswax solid lipid nanoparticles. Means shown with different small letters (a, b) represent significant differences (p<0.05) in the same columns.

2.3.3 Particle size and zeta potential analysis of loaded and unloaded BW. SLNs

The Zetasizer Nano DLS (Silas, France) was used to determine the size and dimension of the samples. The nanoparticles' zeta potential was measured using a Beckman Coulter Delsa nano zeta potential analyzer. The zeta potential of distributed BW. SLNs in deionized water was analyzed at room temperature. Analyses were performed using aqueous dispersions of unloaded and loaded nanoparticles in triplicate.

2.4 Encapsulation efficacy of VD₃ and ω 3

To determine EE%, 1 mL of each nanoparticle solution (VD₃-BW. SLNs and ω 3-BW. SLNs) was centrifuged at 4500 g for 10 min. The upper phase (nanoparticle phase) was extracted and added to 5 mL of acetonitrile. After 30 min of stirring at 1000 rpm, the solution was centrifuged for 10 min at 4500 g. The EE% of VD₃ and ω 3 in VD₃/ ω 3-BW. SLNs was determined separately according to the mentioned method. Afterward, absorption at 265 and 220 nm was measured to calculate VD₃ and ω 3 by UV spectrophotometry, respectively. EE% was calculated using the standard curve and the following equation (Eq. 1) (31, 32):

$$EE\% = \begin{bmatrix} Total amount of loaded vitamin D_3 \text{ or omega } 3 / \\ Initial amount of added vitamin D_3 \text{ or omega } 3 \end{bmatrix} \times 100$$
(1)

2.5 In-vitro VD₃ and ω 3 release study

To investigate the *in-vitro* release profile of VD₃ and ω 3 from BW. SLNs through the use of the dialysis method, the VD₃/ ω 3-BW. SLNs suspension was put inside the dialysis membranes, which had a molecular weight cut-off of 12,000 Da. Afterward, the dialysis tube was inserted into the phosphate buffer saline (PBS, pH: 7.4) and maintained at 30°C at 550 rpm. At predetermined time intervals, 1 mL of samples were collected from the release medium and the quantity of released VD₃ and ω 3 was evaluated using UV spectrophotometry, as described above to determine the entrapment efficiency. Cumulative release of VD₃ and ω 3 was calculated using the following formula (Eq. 2):

Cumulative release (%) =
$$\begin{bmatrix} \text{Released amount of vitamin D3 or omega 3 /} \\ (\text{Total amount of loaded vitamin D3 or omega 3}) \end{bmatrix} \times 100$$
(2)

2.6 Stability of loaded VD₃ and ω 3 in BW. SLNs under alkaline and acidic pH

Stability of free vitamin D₃ (F-VD3), free omega 3 (F- ω 3), and VD₃/ ω 3 loaded in BW. SLNs were determined in pH values of 2 and 9, which the HCl and PBS were used to adjust the pH of formulations. Samples were maintained in the dark for 7 days at room temperature. Then, 1 mL of each sample was taken, and VD₃ and ω 3 were extracted

and quantified by HPLC. The following equation (Eq. 3) was used to determine the stability under different pH values (33):

Stability (%) =
$$\begin{bmatrix} \text{Residual amount of vitamin D}_3 \text{ or omega } 3 \\ \text{Original amount of vitamin D}_3 \text{ or omega } 3 \end{bmatrix} \times 100$$
(3)

2.7 Stability of loaded VD₃ and ω 3 in BW. SLNs under oxidative condition

Hydrogen peroxide (H_2O_2) solution was used to examine the oxidative stability of F-VD₃, F- ω 3, and VD₃/ ω 3 loaded in BW. SLNs. Samples of F-VD3, F- ω 3, and VD3/ ω 3-BW. SLNs were prepared with 0.1, 0.5, and 1% of H₂O₂. The samples were kept in the dark for 2 h at room temperature. 1 mL of samples were collected, and VD₃ and ω 3 were extracted. Then, their oxidative stability was determined by HPLC and assessed by the following equation (Eq. 4) (33):

Oxidative stability (%) =
$$\begin{bmatrix} \text{Residual amount of vitamin D3 or omega 3 /} \\ \text{Original amount of vitamin D3 or omega 3} \end{bmatrix} \times 100$$
(4)

2.8 Stability of zeta potential and size of $VD_3/\omega 3$ -BW. SLNs after 30 days

BW. SLNs loaded with VD₃ and $\omega 3$ in optimal concentrations were stored in a sealed chamber at 4°C for 30 days to evaluate their storage stability. The zeta potential and particle size of VD₃/ $\omega 3$ -BW. SLNs were measured using a dynamic light-scattering instrument. Analyses were carried out in triplicate.

2.9 Statistical analysis

Data was expressed as mean \pm standard deviation of three replicates (n = 3). The experimental results were analyzed with SPSS version 24 and subjected to one-way analysis of variance (ANOVA). Duncan's test was used to calculate the significant differences between mean amounts. In all analyses, p < 0.05 was considered as significant.

3 Result and discussion

3.1 Optimal formulation

The effect of different concentrations of VD₃ (5 and 10 mg) and ω 3 (8 and 10 mg) on entrapment efficiency (EE%) was studied to prepare BW. SLNs with simultaneous high efficiency for loading of VD₃ and ω 3. According to the obtained results in Table 1, the maximum EE of VD₃ (92.3%) and ω 3 (86.3%) was achieved when VD₃ and ω 3 were entrapped in the BW. SLNs simultaneously at concentrations of 5 and 10 mg, respectively. Hence, it was selected as an optimum formulation to perform further tests.

3.2 Size, zeta potential, and morphology analysis of nanoparticles

3.2.1 VD₃/ω3-BW. SLNs

The morphology of nanoparticles was investigated by SEM, as shown in Figure 2. As can be seen, the prepared optimum nanoparticles had a spherical form, and their size was 63.5 ± 4 nm. Nanoparticles' zeta potential was- 32 ± 1.6 mV (Table 2). No aggregation or agglomeration of nanoparticles was seen in the stable aqueous solution of optimal formulation of VD₃/ ω 3-BW. SLNs. It seems that beeswax nanoparticles are a suitable carrier for VD₃ and ω 3. Similarly, Dantas et al. (17) reported that beeswax nanoparticles are capable of high drug loading and have not undergone polymorphic modifications. Also, Mehmood and Ahmed (34) declared that mixed surfactant (Tween 80 and soya lecithin) based nanoemulsions are an effective delivery system for incorporation of vitamin D into food and beverages to overcome the worldwide deficiency of vitamin D.

3.2.2 VD₃-BW. SLNs

After removing $\omega 3$ from the optimal formulation of VD₃/ $\omega 3$ -BW. SLNs, spherical VD₃-BW. SLNs were created and analyzed, which their characteristics were summarized in Table 2. The size and zeta potential of nanoparticles were raised to 66.2 ± 7.3 nm and -36 ± 1.5 mV, respectively. Similar trends were observed from a study conducted by Fan et al. (35). It was stated that unloaded salidroside nanoliposomes with a particle size of under 100 nm have no electric charge on their surface, and the loading of salidroside resulted in a significant increase in the zeta potential of nano-liposomes within the range of -10 to -20 mV. They stated that the dipole tropism is produced and, as a result, the surface electric charge of nanoparticles is enhanced by the interaction between choline and the hydroxyl group of salidroside (35). In the present study, it seems

that the polar region of phosphatidylcholine could interact with the hydroxyl group of VD_3 and consequently enhance the zeta potential of VD_3 -BW. SLNs. Nanoparticle suspension in aqueous solution was extremely stable, and no aggregation or agglomeration of nanoparticles was seen (Figure 2A2).

3.2.3 ω3-BW. SLNs

Spherical ω 3-BW. SLNs were made, and their size was 78.6±5.2 nm. Nanoparticles were mono-modal, although zeta potential was significantly different between ω 3-BW. SLNs and VD₃-BW. SLNs or VD₃/ ω 3-BW. SLNs. Zeta potential of ω 3-BW. SLNs was reduced to -24 mV after encapsulation of ω 3 into BW. SLNs (Table 2).

3.2.4 U-BW. SLNs

U-BW. SLNs were synthesized with a mono-modal distribution and a diameter of 74.2±3.2nm in an aqueous solution (Figure 2A4). U-BW. SLNs exhibited a negative surface charge (-32.7 mV) in the zeta potential study, and nanoparticles were stable in suspension. Zeta potential of U-BW. SLNs changed after VD_3 and $\omega 3$ loading. When the VD₃ was loaded into the BW. SLNs, the nanoparticles' zeta potential increased from-32.70±1.1 mV (unloaded nanoparticles) to-36±1.5 mV (VD₃-BW. SLNs). On the other hand, the entrapment of ω 3 into the BW. SLNs reduced the zeta potential of unloaded nanoparticles from- 32.70 ± 1.1 to -24 ± 0.4 mV in ω 3-BW. SLNs. Intriguingly, the nanoparticles' zeta potential was increased in VD3/w3-BW. SLNs from-24±0.4 to- $32\pm1.6\,\text{mV}$ when $\omega3$ and VD₃ were both simultaneously trapped in the SLNs. The formulations containing only ω 3 demonstrated bigger nanoparticles. The size of nanoparticles was reduced by adding VD₃ to the formulations. Additionally, VD3 increased the zeta potential of ω3-BW. SLNs from-24 to-32 mV in VD₃/ω3-BW. SLNs. The ability of VD₃ to increase the surface charge of BW. SLNs may be the reason for reducing



05

Formulation*	Size (nm)	Zeta potential (mV)	Dispersity	Yield (%)	Vitamin D3 EE (%)	Omega 3 EE (%)
U-BW. SLNs	74.20 ± 3.20^{ab}	$-32.70 \pm 1.10^{\rm b}$	Monomodal	$95.80 \pm 1.50^{\rm a}$	_	-
VD ₃ -BW. SLNs	$66.20 \pm 7.30^{\rm bc}$	-36.00 ± 1.50^{a}	Monomodal	$93.10\pm1.20^{\rm b}$	$67.50\pm0.70^{\rm b}$	-
ω3-BW. SLNs	78.60 ± 5.20^{a}	$-24.00 \pm 0.40^{\circ}$	Monomodal	94.30 ± 1.40^{ab}	_	88.60 ± 1.70^{a}
VD ₃ /ω3-BW. SLNs (optimized)	$63.50 \pm 4.00^{\circ}$	$-32.00 \pm 1.60^{\rm b}$	Monomodal	95.10 ± 0.80^{ab}	92.30 ± 1.20^{a}	86.30 ± 1.50^{a}

TABLE 2 Characteristics of unloaded and loaded BW-SLNs with vitamin D₃ and/or omega 3.

* U-BW. SLNs, unloaded beeswax solid lipid nanoparticles; VD₃-BW. SLNs, vitamin D₃-beeswax solid lipid nanoparticles; ω3-BW. SLNs, omega 3-beeswax solid lipid nanoparticles; VD₃/ω3-BW. SLNs, vitamin D₃/omega 3-beeswax solid lipid nanoparticles. Means shown with different small letters (a, b) represent significant differences (*p* < 0.05) in the same columns.

the nanoparticle size. In accordance with our findings, Xiang et al. (36) mentioned that when the zeta potential of OVA-PEC-VD₃ (ovalbuminhigh methoxyl pectin-VD₃) nanocomplexes decreased due to the reduction of electrostatic repulsions between the particles, their size increased. In a survey conducted by (37), chitosan nanoparticles loaded with *Salvia officinalis* extract exhibit a lower surface charge (+21.8 to +28.8 mV) than unloaded nanoparticles (+32 mV) that is in agreement with our results when ω 3 trapped into BW. SLNs. In our study, the BW. SLNs were more stable in aqueous solution when they had a higher negative surface charge. In accordance with our findings, previous research reported that emulsions with high zeta-potential (positive or negative) indicated more repulsion between particles and were electrically stabilized, whereas coagulation or flocculation could occur between particles with low zeta-potential (38, 39).

3.3 Determination of yield and EE

The yield of prepared loaded and unloaded nanoparticles was between 93 and 96%. EE of ω 3 in ω 3-BW. SLNs and VD₃/ ω 3-BW. SLNs was 88.6 ± 5.2 and $86.3 \pm 1.5\%$, respectively (Table 2). Also, EE of VD₃ in VD₃-BW. SLNs and VD₃/ω3-BW. SLNs was 67.5±1.6 and 92.3±1.2%, respectively. However, the EE of VD3 in VD3/w3-BW. SLNs was much higher than VD₃-BW. SLNs. It's interesting to note that when VD₃ and ω_3 were loaded simultaneously into the nanoparticles, the maximum EE for VD₃ (92.3%) was achieved. According to the findings, the EE of VD₃ increased whenever $\omega 3$ was present in the formulations. The encapsulation effectiveness of pharmaceuticals may increase or decrease depending on factors such as crystallinity and polymorphism of solid lipid-based nanoparticles (40, 41). When ω 3 is added to formulations of beeswaxbased nanoparticles, it may decrease the melting point of SLNs (42) or alter the crystallinity of solid lipid nanoparticles (43). This may increase the solubility of VD₃, which could increase its interaction with the beeswax-lecithin lipid phase and, subsequently, the efficacy of entrapment in BW. SLNs. Ahmad et al. (44) fabricated micro and nanoparticles of chestnut starch for co-encapsulation of vitamins D, E, B₁, and B₂. They stated that the highest encapsulation efficiency of vitamin D (46.27%) was obtained when it was encapsulated in nano-sized starch (44). This is attributed to the larger surface area of nanocarriers compared to micronsized carriers (45).

3.4 In-vitro release study of VD₃ and ω 3 from BW. SLNs

The cumulative release of VD₃ and ω 3 was assessed using the dialysis technique in PBS (pH 7.4), 550 rpm at 30°C (Figures 3A,B).

Three release phases were observed and monitored: the first initial burst release phase (IBR), which lasted between 1 and 3 h; the second release phase, which lasted between 3 and 24 h; and the third release phase, which lasted between 24 and 168 h. During 3 h incubation, the IBR of $\omega 3$ and VD_3 was measured. The IBR was 19.4 and 9.3% for $\omega 3$ and VD₃, respectively (Figure 3B). The IBR may be associated with molecules of $\omega 3$ and VD₃ that are poorly adsorbed on the surface of nanoparticles (46). The cumulative release of ω 3 and VD₃ increased to 28.7 and 14.1%, respectively, during the second phase (3-24 h). These data from the second phase demonstrated that $\omega 3$ was released into the buffer twice as much as VD₃. After 168 h, the release of ω 3 and VD₃ reached 48.2 and 36.5% of the total entrapped ω 3 and VD₃, respectively (Figure 3A). It indicates that more than 52 and 63% of ω 3 and VD₃, respectively, remained caught in the BW. SLNs after 168 h. similarly, Hosseini et al. (47) noticed the same early and then gradual emissions of oregano essential oil. Moreover, Shakeri et al. (31) used beeswax nanoparticles to co-encapsulate astaxanthin and carvacrol. They reported that BW. SLNs could slowly release astaxanthin and carvacrol in a buffer, which is in consistent with the present study results. The release of carvacrol and astaxanthin after 168h was 45.8 and 33.62% of total entrapped carvacrol and astaxanthin (31). Diffusion and hydrolytic degradation (erosion) are two important mechanisms for drug release from SLNs. SLNs degrade in the presence of water by an ester hydrolysis reaction that is acid-catalyzed and reversible (48). A better release profile and higher retention of encapsulated bioactive compounds occur due to the protective effects of encapsulation (49).

3.5 Stability of VD_3/ ω 3-BW. SLNs under acidic and alkaline pH

The stability of free VD₃ (F-VD₃), free ω 3 (F- ω 3), and encapsulated VD₃ and ω 3 was investigated in aqueous solutions with pH 9.0 and 2.0. The stability of F- ω 3 at an acidic pH of 2 was found to be 81.5, 69.9 and 55.4% after 1, 72, and 168 h, respectively (Figure 4A). After 168h of incubation at an acidic pH, entrapped $\omega 3$ was more stable and more than 80% of loaded molecules remained intact in nanoparticles in acidic conditions. After 168 h of incubation under alkaline conditions, only 51.3% of the free ω 3 were still intact because $\omega 3$ was sensitive to an alkaline pH (pH 9) (Figure 4B). During 168 h of incubation at an alkaline pH, BW. SLNs increased the stability of the encapsulated $\omega 3$ to 75.5%. In accordance with the present work, Campos et al. (50) demonstrated that using wax or lipids to form a nanoparticle matrix can enhance the stability of entrapped compounds. The susceptibility of free and entrapped VD₃ to pH changes was higher than that of free and entrapped $\omega 3$ molecules. The stability of free VD₃ molecules was



retained at a rate of 50.26% under pH of 2 after 1h, which subsequently decreased to 37.2% after 168h of incubation (Figure 4C). Stability of entrapped VD₃ under acidic conditions was obtained at 75.2, 74.31 and 69.23% during 1, 72 and 168h, respectively. Similar to acidic pH, alkaline pH had adverse effects on free molecules of VD_3 , and after 168 h, it affected more than 58% of these molecules (Figure 4D). Therefore, it could be inferred that the ω 3 and VD₃ molecules that are trapped within BW. SLNs are shielded from the negative effects of alkaline or acidic pH. Our findings are in agreement with the studies of Qian et al. (51). Their findings demonstrated that beta-carotene degradation is promoted in acidic conditions (pH=3) (51). Also, in a study conducted by Mitbumrung et al. (52), due to the sensitivity of VD₃ to acidic pH, the EE of entrapped VD₃ in Pickering emulsions (10% wt soybean oil-in-water) stabilized by nanofibrillated cellulose reduced at pH 2. In contrast to our findings, Park et al. (53) found encapsulated VD₃ in nanostructured lipid carriers was stable in acidic conditions, and the EE was about 75% in all pH conditions (pH 2.0, 4.0, and 10), which indicates that pH does not affect it.

3.6 Stability of VD₃/ ω 3-BW. SLNs under oxidative condition (H₂O₂)

In different concentrations of H_2O_2 solutions (0.1, 0.5, and 1% v/v), the oxidation stability of F-VD₃, F- ω 3, and encapsulated VD₃

and ω 3 in BW. SLNs was examined. The results demonstrated that $F\text{-}VD_3$ and $F\text{-}\omega3$ were more sensitive to H_2O_2 oxidation (Figures 5A,B). However, VD₃/ ω 3-BW. SLNs showed higher oxidation resistance for VD₃ and ω 3, so 96.2 and 90.4% of entrapped VD₃ and ω3 remained intact in nanoparticles at highly oxidizing conditions (H₂O₂: 1% v/v). The incorporation of VD₃ and ω 3 in lipid nucleation, which restricts their exposure to oxidative agents, may be the reason for preventing the oxidation of VD_3 and $\omega 3$ (33). Similar results were obtained in the study of Eratte et al. (54), in which encapsulated ω 3 fatty acids in microcapsules of whey protein isolate and gum Arabic showed stronger oxidative stability compared to untreated samples. Also, Xiao et al. (23) used a complex of alginate and ovalbumin to co-encapsulate omega-3 fatty acids with curcumin, lutein, and essential oils, and the highest oxidative stability was obtained in treatments containing omega-3 fatty acids and garlic essential oil during one-month of storage.

3.7 Stability of zeta potential and size of $VD_3/\omega 3$ -BW. SLNs during the time

Size and zeta potential of VD₃/ ω 3-BW. SLNs suspensions were analyzed after 1 month of storage at 4°C. The findings showed that zeta potential and size were altered from -32 mV and 63.5 nm to -27 mV and 84.2 nm, respectively (Figure 6). However, no aggregation of nanoparticles was observed in the suspensions even



FIGURE 4

Stability of F- ω 3 and entrapped ω 3 in BW. SLNs under acidic pH (A) and alkaline pH (B). Stability of F-VD3 and entrapped VD3 in BW. SLNs under acidic pH (C) and alkaline pH (D).



after 1 month. This is in agreement with the findings of Andrade Chaves et al. (55), who reported an increase in the size of liposomes loaded with curcumin and vitamin D3 during 42 days of storage. In addition, a decrease in zeta potential occurred during the storage periods that, external exposure of phosphate and absorption of OH-from the water environment were mentioned as the reasons for the negative value of zeta potential (55). In a survey conducted on $\omega 3$ and α -tocopherol co-encapsulated in a nano lipid carrier, the appropriate zeta potential (-1.1 mV) and particle size (110 nm) were obtained after 75 days of storage at 25°C, which indicated a relatively low tendency of nanoparticles to agglomerate and their good stability (22). Campos et al. (56) stated that mannitol at a concentration of 10% (w/v) was an appropriate cryoprotectant for suspensions of nanoparticles and SLNs containing phenolic compounds during 3 months of storage. In our research, the storage stability of SLNs in suspension was assessed without the use of cryoprotectants, and the nanoparticles remained stable during 30 days of storage.

4 Conclusion

In the present study, omega-3 and vitamin D₃ were successfully co-loaded into beeswax solid lipid nanoparticles. Change in EE of bioactive ingredients depending on the concentration of the core solution was observed. The simultaneous encapsulation of VD_3 and $\omega 3$ at concentrations 5 and 10 mg, respectively, showed the highest encapsulation efficiency and spherical nanocapsules with the lowest size (63.5 nm), which was selected as an optimum formulation. In vitro, release study indicated that 19.4 and 9.3% of ω 3 and VD₃ could be absorbed on nanoparticle surfaces and quickly released into the buffer solution. Further, BW. SLNs were effective in protecting both bioactives from oxidative conditions and high pH levels. The VD₃/ω3-BW. SLNs nanocomplexes have good storage stability and no agglomerate or aggregate was observed after 30 days of storage at 4°C. Hence, nanoparticles showed high stability against harsh conditions, which is important for the use



of sensitive nutrients. The co-encapsulated omega-3 and vitamin D_3 in beeswax solid lipid nanoparticles could efficiently be used in the food industry to develop functional products. The increasing demand for functional foods containing healthpromoting ingredients strengthens the importance of research in this field. There are still some limits to our knowledge about the use of other waxes in different proportions, with beeswax as carriers to encapsulate bioactive molecules. Since beeswax nanoparticles are a good carrier and have a suitable loading capacity, it is suggested to load various fat-soluble vitamins, essential oils, antibiotic compounds, and post-biotic compounds into them in future research.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

Author contributions

MS: Conceptualization, Data curation, Investigation, Validation, Writing – original draft. RG: Conceptualization, Data curation, Visualization, Writing – original draft. SS: Methodology, Project administration, Supervision, Writing – review & editing. EK: Formal analysis, Methodology, Resources, Validation, Writing – review & editing. NM-M: Conceptualization, Validation, Visualization, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study is related to the project NO. IR.SBMU.nnftri.Rec.1399.030 from National Nutrition and Food Technology Research Institute (NNFTRI), Shahid Beheshti University of Medical Sciences, Tehran, Iran. We also appreciate National Nutrition and Food Technology Research Institute (NNFTRI) and Shahid Beheshti University of Medical Sciences for their financial support of this study.

Acknowledgments

We gratefully thank from the National Nutrition and Food Technology Research Institute (NNFTRI) and Shahid Beheshti University of Medical Sciences of Iran for the efforts in promoting the knowledge and this work was supported financially by them.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

References

1. Rezaei A, Fathi M, Jafari SM. Nanoencapsulation of hydrophobic and low-soluble food bioactive compounds within different nanocarriers. *Food Hydrocoll.* (2019) 88:146–62. doi: 10.1016/j.foodhyd.2018.10.003

2. Liu K, Chen Y-Y, Pan L-H, Li Q-M, Luo J-P, Zha X-Q. Co-encapsulation systems for delivery of bioactive ingredients. *Food Res Int.* (2022) 155:111073. doi: 10.1016/j. foodres.2022.111073

3. Azar F, Pezeshki A, Ghanbarzadeh B, Hamishehkar H, Mohammadi M. Nanostructured lipid carriers: promising delivery systems for encapsulation of food ingredients. *J Agric Food Res.* (2020) 2:100084. doi: 10.1016/j.jafr.2020.100084

4. Esfanjani AF, Assadpour E, Jafari SM. Improving the bioavailability of phenolic compounds by loading them within lipid-based nanocarriers. *Trends Food Sci Technol.* (2018) 76:56–66. doi: 10.1016/j.tifs.2018.04.002

5. Subramanian P. Lipid-based nanocarrier system for the effective delivery of nutraceuticals. *Molecules*. (2021) 26:5510. doi: 10.3390/molecules26185510

6. Patra JK, Shin H-S, Paramithiotis S. Application of nanotechnology in food science and food microbiology. *Front Microbiol.* (2018) 9:714. doi: 10.3389/fmicb.2018.00714

7. Ariyarathna IR, Rajakaruna R, Karunaratne DN. The rise of inorganic nanomaterial implementation in food applications. *Food Control.* (2017) 77:251–9. doi: 10.1016/j. foodcont.2017.02.016

8. Bott J, Störmer A, Franz R. "A comprehensive study into the migration potential of nano silver particles from food contact polyolefins," in *Chemistry of food, food supplements, and food contact materials: from production to plate.* eds. M. A. Benvenuto, S. Ahuja, T. V. Duncan, G. O. Noonan and E. S. Roberts-Kirchhoff (Washington: ACS Publications)(2014). 51–70.

9. Augustin M, Sanguansri L. "Encapsulation of bioactives," in *Food materials science:* principles and practice.eds. J. M. Aguilera and P. J. Lillford (New York: Springer)(2008). 577–601.

10. Shirodkar RK, Kumar L, Mutalik S, Lewis S. Solid lipid nanoparticles and nanostructured lipid carriers: emerging lipid based drug delivery systems. *Pharm Chem J.* (2019) 53:440–53. doi: 10.1007/s11094-019-02017-9

11. Borges A, de Freitas V, Mateus N, Fernandes I, Oliveira J. Solid lipid nanoparticles as carriers of natural phenolic compounds. *Antioxidants*. (2020) 9:998. doi: 10.3390/antiox9100998

12. Dhiman N, Awasthi R, Sharma B, Kharkwal H, Kulkarni GT. Lipid nanoparticles as carriers for bioactive delivery. *Front Chem.* (2021) 9:580118. doi: 10.3389/fchem.2021.580118

13. Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. *Adv Pharm Bull.* (2015) 5:305–13. doi: 10.15171/apb.2015.043

14. Vyas S, Rai S, Paliwal R, Gupta PN, Khatri K, Goyal AK, et al. Solid lipid nanoparticles (SLNs) as a rising tool in drug delivery science: one step up in nanotechnology. *Curr Nanosci.* (2008) 4:30–44. doi: 10.2174/157341308783591816

15. Tang C-H, Chen H-L, Dong J-R. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) as food-grade nanovehicles for hydrophobic nutraceuticals or bioactives. *Appl Sci.* (2023) 13:1726. doi: 10.3390/app13031726

16. Galvão JG, Santos RL, Lira AAM, Kaminski R, Sarmento VH, Severino P, et al. Stearic acid, beeswax and carnauba wax as green raw materials for the loading of carvacrol into nanostructured lipid carriers. *Appl Sci.* (2020) 10:6267. doi: 10.3390/app10186267

17. Dantas IL, Bastos KTS, Machado M, Galvao JG, Lima AD, Gonsalves JKMC, et al. Influence of stearic acid and beeswax as solid lipid matrix of lipid nanoparticles containing tacrolimus. *J Therm Anal Calorim.* (2018) 132:1557–66. doi: 10.1007/ s10973-018-7072-7

18. Shaltooki P, Farahbakhsh A. Encapsulation of material using bees wax. International Conference on Research in Science and Technology. kualalumpur-Malaysia (2015) 1–8. Available at: https://scholar.google.com/scholar?hl=en&as_sdt= 0%2C5&q=Encapsulation+of+material+using+bees+wax&btnG=

19. Giampieri F, Quiles JL, Cianciosi D, Forbes-Hernández TY, Orantes-Bermejo FJ, Alvarez-Suarez JM, et al. Bee products: an emblematic example of underutilized sources of bioactive compounds. *J Agric Food Chem.* (2022) 70:6833–48. doi: 10.1021/acs. jafc.1c05822

20. Pourmadadi M, Abbasi P, Eshaghi MM, Bakhshi A, Manicum A-LE, Rahdar A, et al. Curcumin delivery and co-delivery based on nanomaterials as an effective approach for cancer therapy. *J Drug Deliv Sci Technol.* (2022) 78:103982. doi: 10.1016/j. jddst.2022.103982

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

21. Chawda PJ, Shi J, Xue S, Young QS. Co-encapsulation of bioactives for food applications. *Food Qual Saf.* (2017) 1:302–9. doi: 10.1093/fqsafe/fyx028

22. Shahparast Y, Eskandani M, Rajaei A, Khosroushahi AY. Preparation, physicochemical characterization and oxidative stability of omega-3 fish oil/ α -tocopherol-co-loaded nanostructured lipidic carriers. *Adv Pharm Bull.* (2019) 9:393–400. doi: 10.15171/apb.2019.046

23. Xiao S, Ahn DU. Co-encapsulation of fish oil with essential oils and lutein/ curcumin to increase the oxidative stability of fish oil powder. *Food Chem.* (2023) 410:135465. doi: 10.1016/j.foodchem.2023.135465

24. Tchuenbou-Magaia FL, Tolve R, Anyadike U, Giarola M, Favati F. Co-encapsulation of vitamin D and rutin in chitosan-zein microparticles. *J Food Meas Charact.* (2022) 16:2060–70. doi: 10.1007/s11694-022-01340-2

25. Saini RK, Keum Y-S. Omega-3 and omega-6 polyunsaturated fatty acids: dietary sources, metabolism, and significance—a review. *Life Sci.* (2018) 203:255–67. doi: 10.1016/j.lfs.2018.04.049

26. Wang J, Han L, Wang D, Sun Y, Huang J, Shahidi F. Stability and stabilization of omega-3 oils: a review. *Trends Food Sci Technol.* (2021) 118:17–35. doi: 10.1016/j. tifs.2021.09.018

27. Chaves MA, Baldino L, Pinho SC, Reverchon E. Co-encapsulation of curcumin and vitamin D3 in mixed phospholipid nanoliposomes using a continuous supercritical CO2 assisted process. *J Taiwan Inst Chem Eng.* (2022) 132:104120. doi: 10.1016/j. jtice.2021.10.020

28. Santos MB, de Carvalho MG, Garcia-Rojas EE. Carboxymethyl tara gumlactoferrin complex coacervates as carriers for vitamin D3: encapsulation and controlled release. *Food Hydrocoll*. (2021) 112:106347. doi: 10.1016/j.foodhyd.2020.106347

29. Bilezikian JP, Formenti AM, Adler RA, Binkley N, Bouillon R, Lazaretti-Castro M, et al. Vitamin D: dosing, levels, form, and route of administration: does one approach fit all? *Rev Endocr Metab Disord*. (2021) 22:1201–18. doi: 10.1007/s11154-021-09693-7

30. Bouillon R, Antonio L, Olarte OR. Calcifediol (250H vitamin D3) deficiency: a risk factor from early to old age. *Nutrients*. (2022) 14:1168. doi: 10.3390/nu14061168

31. Shakeri M, Razavi SH, Shakeri S. Carvacrol and astaxanthin co-entrapment in beeswax solid lipid nanoparticles as an efficient nano-system with dual antioxidant and anti-biofilm activities. *Lwt.* (2019) 107:280–90. doi: 10.1016/j.lwt.2019.03.031

32. Olloqui EJ, Castañeda-Ovando A, Contreras-López E, Hernandez-Sanchez D, Tapia-Maruri D, Piloni-Martini J, et al. Encapsulation of fish oil into low-cost alginate beads and EPA-DHA release in a rumino-intestinal in vitro digestion model. *Eur J Lipid Sci Technol.* (2018) 120:1800036. doi: 10.1002/ejlt.201800036

33. Li M, Zahi MR, Yuan Q, Tian F, Liang H. Preparation and stability of astaxanthin solid lipid nanoparticles based on stearic acid. *Eur J Lipid Sci Technol.* (2016) 118:592–602. doi: 10.1002/ejlt.201400650

34. Mehmood T, Ahmed A. Tween 80 and soya-lecithin-based food-grade nanoemulsions for the effective delivery of vitamin D. *Langmuir*. (2020) 36:2886–92. doi: 10.1021/acs.langmuir.9b03944

35. Fan M, Xu S, Xia S, Zhang X. Preparation of salidroside nano-liposomes by ethanol injection method and in vitro release study. *Eur Food Res Technol.* (2008) 227:167–74. doi: 10.1007/s00217-007-0706-9

36. Xiang C, Gao J, Ye H, Ren G, Ma X, Xie H, et al. Development of ovalbumin-pectin nanocomplexes for vitamin D3 encapsulation: enhanced storage stability and sustained release in simulated gastrointestinal digestion. *Food Hydrocoll*. (2020) 106:105926. doi: 10.1016/j.foodhyd.2020.105926

37. da Silva SB, Amorim M, Fonte P, Madureira R, Ferreira D, Pintado M, et al. Natural extracts into chitosan nanocarriers for rosmarinic acid drug delivery. *Pharm. Biol.* (2015) 53:642–652. doi: 10.3109/13880209.2014.935949

38. Surh J, Decker EA, McClements DJ. Properties and stability of oil-in-water emulsions stabilized by fish gelatin. *Food Hydrocoll*. (2006) 20:596–606. doi: 10.1016/j. foodhyd.2005.06.002

39. Mosqueira VCF, Legrand P, Pinto-Alphandary H, Puisieux F, Barratt G. Poly (D, L-lactide) nanocapsules prepared by a solvent displacement process: influence of the composition on physicochemical and structural properties. *J Pharm Sci.* (2000) 89:614–26. doi: 10.1002/(SICI)1520-6017(200005)89:5<614::AID-JPS7>3.0.CO;2-7

40. Jores K, Mehnert W, Drechsler M, Bunjes H, Johann C, Mäder K. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. *J Control Release*. (2004) 95:217–27. doi: 10.1016/j. jconrel.2003.11.012

41. Severino P, Pinho SC, Souto EB, Santana MH. Polymorphism, crystallinity and hydrophilic–lipophilic balance of stearic acid and stearic acid–capric/caprylic triglyceride matrices for production of stable nanoparticles. *Colloids Surf B: Biointerfaces.* (2011) 86:125–30. doi: 10.1016/j.colsurfb.2011.03.029

42. Kumar S, Randhawa JK. High melting lipid based approach for drug delivery: solid lipid nanoparticles. *Mater Sci Eng C*. (2013) 33:1842–52. doi: 10.1016/j.msec.2013.01.037

43. Souto E, Wissing S, Barbosa C, Müller R. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. *Int J Pharm*. (2004) 278:71–7. doi: 10.1016/j.ijpharm.2004.02.032

44. Ahmad M, Hassan I, Shah M, Gani A, Muthukumarappan K. Co-encapsulation of multivitamins in micro & nano-sized starch, target release, capsule characterization and interaction studies. *Int J Biol Macromol.* (2023) 240:124367. doi: 10.1016/j. ijbiomac.2023.124367

45. Wen J, Chen G, Alany RG. "Theories and concepts of Nano materials, Nano-and microencapsulation," in *Nano-and microencapsulation for foods*. ed. H. S. Kwak Wiley-Blackwell, (2014). 15–42.

46. Campos EV, Proença PL, Oliveira JL, Pereira AE, de Morais Ribeiro LN, Fernandes FO, et al. Carvacrol and linalool co-loaded in β -cyclodextrin-grafted chitosan nanoparticles as sustainable biopesticide aiming pest control. *Sci Rep.* (2018) 8:7623. doi: 10.1038/s41598-018-26043-x

47. Hosseini SF, Zandi M, Rezaei M, Farahmandghavi F. Two-step method for encapsulation of oregano essential oil in chitosan nanoparticles: preparation, characterization and in vitro release study. *Carbohydr Polym.* (2013) 95:50–6. doi: 10.1016/j.carbpol.2013.02.031

48. Hurrell S, Cameron RE. The effect of buffer concentration, pH and buffer ions on the degradation and drug release from polyglycolide. *Polym Int.* (2003) 52:358–66. doi: 10.1002/pi.1164

49. Bajaj SR, Marathe SJ, Singhal RS. Co-encapsulation of vitamins B12 and D3 using spray drying: wall material optimization, product characterization, and release kinetics. *Food Chem.* (2021) 335:127642. doi: 10.1016/j.foodchem.2020.127642

50. Campos DA, Madureira AR, Sarmento B, Gomes AM, Pintado MM. Stability of bioactive solid lipid nanoparticles loaded with herbal extracts when exposed to simulated gastrointestinal tract conditions. *Food Res Int.* (2015) 78:131–40. doi: 10.1016/j.foodres.2015.10.025

51. Qian C, Decker EA, Xiao H, McClements DJ. Physical and chemical stability of β -carotene-enriched nanoemulsions: influence of pH, ionic strength, temperature, and emulsifier type. *Food Chem.* (2012) 132:1221–9. doi: 10.1016/j.foodchem.2011.11.091

52. Mitbumrung W, Suphantharika M, McClements DJ, Winuprasith T. Encapsulation of vitamin D3 in Pickering emulsion stabilized by nanofibrillated mangosteen cellulose: effect of environmental stresses. *J Food Sci.* (2019) 84:3213–21. doi: 10.1111/1750-3841.14835

53. Park SJ, Garcia CV, Shin GH, Kim JT. Development of nanostructured lipid carriers for the encapsulation and controlled release of vitamin D3. *Food Chem*. (2017) 225:213–9. doi: 10.1016/j.foodchem.2017.01.015

54. Eratte D, McKnight S, Gengenbach TR, Dowling K, Barrow CJ, Adhikari BP. Coencapsulation and characterisation of omega-3 fatty acids and probiotic bacteria in whey protein isolate–gum Arabic complex coacervates. *J Funct Foods*. (2015) 19:882–92. doi: 10.1016/j.jff.2015.01.037

55. Chaves MA, Oseliero Filho PL, Jange CG, Sinigaglia-Coimbra R, Oliveira CLP, Pinho SC. Structural characterization of multilamellar liposomes coencapsulating curcumin and vitamin D3. *Colloids Surf A Physicochem Eng Asp.* (2018) 549:112–21. doi: 10.1016/j.colsurfa.2018.04.018

56. Campos DA, Madureira AR, Sarmento B, Pintado MM, Gomes AM. Technological stability of solid lipid nanoparticles loaded with phenolic compounds: drying process and stability along storage. *J Food Eng.* (2017) 196:1–10. doi: 10.1016/j. jfoodeng.2016.10.009